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Abstract 
Purpose: Respiratory muscle weakness frequently develops in critically ill patients and is associated with adverse 
outcome, including difficult weaning from mechanical ventilation. Today, no drug is approved to improve respira-
tory muscle function in these patients. Previously, we have shown that the calcium sensitizer levosimendan improves 
calcium sensitivity of human diaphragm muscle fibers in vitro and contractile efficiency of the diaphragm in healthy 
subjects. The main purpose of this study is to investigate the effects of levosimendan on diaphragm contractile effi-
ciency in mechanically ventilated patients.
Methods: In a double-blind randomized placebo-controlled trial, mechanically ventilated patients performed two 
30-min continuous positive airway pressure (CPAP) trials with 5-h interval. After the first CPAP trial, study medication 
(levosimendan 0.2 µg/kg/min continuous infusion or placebo) was administered. During the CPAP trials, electrical 
activity of the diaphragm  (EAdi), transdiaphragmatic pressure (Pdi), and flow were measured. Neuromechanical effi-
ciency (primary outcome parameter) was calculated.
Results: Thirty-nine patients were included in the study. Neuromechanical efficiency was not different during the 
CPAP trial after levosimendan administration compared to the CPAP trial before study medication. Tidal volume 
and minute ventilation were higher after levosimendan administration (11 and 21%, respectively), whereas EAdi 
and Pdi were higher in both groups in the CPAP trial after study medication compared to the CPAP trial before study 
medication.
Conclusions: Levosimendan does not improve diaphragm contractile efficiency.
Keywords: Diaphragm, Critical-illness-associated respiratory muscle weakness, Mechanical ventilation weaning, 
Calcium sensitization, Levosimendan
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Introduction
Respiratory muscle weakness frequently develops in ven-
tilated critically ill patients and is associated with adverse 
outcome, including difficult weaning from mechani-
cal ventilation [1–10]. Therefore, strategies that aim to 
improve respiratory muscle function are much needed. 
Today, no drug is approved for the treatment of respira-
tory muscle weakness [11].
Muscle weakness may result from loss of contractile 
proteins (atrophy) or contractile protein dysfunction. 
Indeed, atrophy of the diaphragm has been demonstrated 
in critically ill ventilated patients using ultrasound [8] 
and muscle biopsies [12, 13]. Recently, we found evidence 
for contractile protein dysfunction in diaphragm muscle 
fibers of ventilated intensive care unit (ICU) patients [12]. 
Diaphragmatic muscle fibers of these patients exhibit 
reduced calcium sensitivity of contraction [14], resulting 
in decreased force generation at submaximal intracellu-
lar calcium concentration [12]. Levosimendan, a cardiac 
inotrope that augments the calcium sensitivity of the tro-
ponin complex, has been shown to improve cardiac mus-
cle contractility and is approved for clinical application 
worldwide for treatment of heart failure [15, 16].
In an experimental study, we demonstrated that levo-
simendan improves in vitro force generation of slow and 
fast twitch muscle fibers obtained from the diaphragm 
of patients with chronic obstructive pulmonary dis-
ease (COPD), but also from fibers obtained from elec-
tive surgery patients without comorbidities [17]. More 
recently, we demonstrated that levosimendan improves 
in vivo contractile efficiency of the diaphragm in healthy 
subjects [18]. Whether levosimendan improves in  vivo 
contractile efficiency of the diaphragm in ICU patients 
has not been evaluated. Based on our previous studies 
in vitro [17] and in vivo [18], we hypothesized that levo-
simendan improves diaphragm contractile efficiency in 
patients weaning from mechanical ventilation. We con-
ducted a double-blinded randomized placebo-controlled 
trial that aims to investigate the effects of levosimendan 
on respiratory muscle function, especially diaphragm 
contractile efficiency in ventilated ICU patients.
Methods
Study design and population
The study was a double-blind randomized placebo-
controlled trial conducted in the ICU of the Radboud 
University Nijmegen Medical Center. Inclusion criteria 
were invasive mechanical ventilation for at least 3  days, 
inspiratory pressure support (PS) ≤ 10  cmH2O, posi-
tive end-expiratory pressure (PEEP) ≤ 10  cmH2O, P/F 
ratio ≥ 200  mmHg, hemodynamically stable (systolic 
blood pressure ≥ 110  mmHg without or with low dose 
vasopressors), and able to sustain a 30-min continuous 
positive airway pressure (CPAP) trial. Exclusion crite-
ria were neuromuscular disorder before ICU admission, 
new onset cardiac arrhythmias, left ventricle ejection 
fraction < 35%, severe kidney failure (serum creatinine 
> 150  µmol/L), pregnancy or contra-indication for the 
placement of nasogastric tube (upper airway or esopha-
geal pathology, recent nasal bleeding). The protocol was 
approved by the local ethical committee and registered 
at ClinicalTrials.gov (NCT01721434). Written informed 
consent was obtained from the legal representative 
before inclusion.
Trial design
Patients were ventilated with the Servo-i ventilator 
(Maquet, Sölna, Sweden). After enrollment, a multi-elec-
trode nasogastric catheter with esophageal and gastric 
balloon (NeuroVent Research Inc, Toronto, Canada) was 
inserted through the nose. The catheter was positioned 
to obtain the best electrical activity of the diaphragm 
 (EAdi) signal using software supplied with the ventilator 
[19].  EAdi is a processed electromyographic (EMG) signal 
obtained from an esophageal multi-electrode recording 
of the diaphragm. The exact processing algorithm is pro-
prietary, but roughly based on the processing algorithms 
of Sinderby and colleagues [20–22]. All patients were 
already equipped with an arterial catheter for blood pres-
sure monitoring, a pulse oximeter, and ECG monitoring. 
Allocation to placebo or levosimendan occurred by block 
design (ratio of 1:1 to receive placebo or levosimendan). 
Placebo (riboflavin sodium phosphate 0.4 mg, dehydrated 
alcohol 100 mg and water 1 mL), and levosimendan were 
indistinguishable (both yellowish) to assure appropri-
ate blinding. Each patient performed two 30-min CPAP 
trails with 5  h in between. During these two CPAP tri-
als, inspiratory assist was reduced to zero, while PEEP 
level was maintained as determined by the treating phy-
sician. Thirty minutes after the first CPAP trial [i.e., at 
study time (hours:minutes) T = 1:00], study medication 
[levosimendan 0.2 µg/kg/min or placebo (equal volume)] 
was administered intravenously till 30 min after the sec-
ond CPAP trial. Arterial blood was withdrawn before and 
after CPAP trials. After the second CPAP trial, the study 
ended and standard clinical treatment was continued.
Take‑home message 
The calcium sensitizer levosimendan is approved as a cardiac ino-
trope, but preliminary studies have shown that it may also improve 
respiratory muscle function. This randomized placebo controlled 
trial shows that levosimendan improves tidal volume, minute venti-
lation and lowers arterial  CO2 in patients weaning from mechanical 
ventilation.
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Data acquisition
Airway flow and processed EAdi were obtained (sam-
pling rate 100 Hz) by connecting a RS-232 cable via the 
serial port of the Servo-i to a personal computer and 
resampled to 2 kHz. Esophageal (Pes) and gastric pres-
sures (Pga) were obtained (sampling rate 2  kHz) from 
the two balloons mounted on the esophageal catheter 
and connected to two differential pressure transducers 
(range ± 50  kPa, Freescale, Tempe, AR) and A/D con-
verter (DT3004; Data Translation, USA). All signals 
were acquired continuously and synchronously using 
dedicated software (NeuroVent Research Inc, Toronto, 
Canada). Signals were analyzed offline using Matlab 
R2014b (Mathworks, Natick, MA, USA).
Data analysis
Transdiaphragmatic pressure (Pdi) was calculated as 
Pga minus Pes, from this, ΔPdi was defined as the differ-
ence between the start of increase in Pdi and the peak 
value of Pdi during inspiration. Inspiratory flow was 
integrated for the calculation of tidal volume (TV). Res-
piratory rate, minute ventilation, and inspiratory time 
(Ti) were determined from the flow signal. ΔEAdi was 
computed as the peak from the processed  EAdi signal 
obtained from the Servo-i during inspiration. Neuro-
mechanical efficiency (NME) was calculated as ΔPdi/
ΔEAdi. Intrinsic PEEP (PEEPi) was computed as the dif-
ference in pressure between start of increase in Pdi and 
start of inspiratory flow [23]. P0.1, a measure of respira-
tory drive, was calculated as the decrease in Pes during 
the first 100 ms of inspiration [24]. Dynamic lung com-
pliance (Cdyn) was computed as TV/ΔPes.
Data were analyzed on a breath-by-breath basis 
and averaged over a 2-min period free of artifacts or 
esophageal or gastric contractions. For each CPAP 
trial, four points in time were analyzed: study time 
(hours:minutes) T = 0:01, 0:05, 0:15, and 0:30 for CPAP 
1 and T = 5:31, 5:35, 5:45, and 6:00 for CPAP 2.
Sample size calculation and statistical analysis
The primary outcome parameter is the difference in 
diaphragm NME response between placebo and levosi-
mendan. NME was calculated at the end of both 30-min 
CPAP trials before and after study medication. Previ-
ously, we found a mean NME of 1.3  cmH2O/µV with 
a standard deviation of 0.5  cmH2O/µV, in response to 
administration of levosimendan neuromechanical effi-
ciency increased by 21% [18]. Therefore, if we expect in 
the current study an increase in neuromechanical effi-
ciency of 25%, this would mean a minimal detected dif-
ference of 0.33  cmH2O/µV. When we assume a type I 
error of 0.05 (two sided) and type II error of 0.80, the 
calculated sample size is 19 patients per study arm.
Statistical analysis was performed using IBM SPSS Sta-
tistics version 22 (IBM Corp, Armonk, New York, USA). 
Continuous variables were compared using a Student’s t 
test in case data had a normal distribution and Mann–
Whitney U test in case of a non-normal distribution. A 
Chi-square test with either normal approximation or 
Fisher’s exact test was used to compare nominal cat-
egorical variables. To assess the effect of levosimendan 
on respiratory and hemodynamic parameters, a two-way 
repeated measures ANOVA was used, with time (for res-
piratory parameters study time (hours:minutes) T = 0:30 
and 6:00; in addition, for hemodynamic parameters also 
at T = 0:01, 1:00 and 5:31) as the within-subject factor 
and group (study medication) as the between-subject 
factor. In case data were non-normally distributed, first, 
a log transformation was performed to obtain a normal 
distribution. Data are presented as mean ± SEM in case 
of a normal distribution and median (IQR) as stated oth-
erwise. A two-tailed P < 0.05 was considered statistically 
significant.
Results
Patient characteristics
Thirty-nine subjects received study medication and com-
pleted the entire study protocol. Baseline characteristics 
for both groups are shown in Table 1. Two subjects were 
excluded from analysis of the primary endpoint (one 
from the placebo and one from the levosimendan group), 
one due to technical issues related to the nasogastric 
catheter, and another due to low  EAdi precluding analysis 
of the primary endpoint. From the remaining subjects, 18 
received placebo and 19 received levosimendan.
Effects of levosimendan on respiratory variables
Table  2 shows the absolute NME (ΔPdi/ΔEAdi) and 
Fig.  1a shows the normalized NME (NME normal-
ized with respect to start of the CPAP trial without 
study medication [i.e. T = 0:01] over the course of the 
study. As expected, NME before study medication was 
not different between groups at start of the first CPAP 
trial and remained stable during the first CPAP trial 
in both groups. Levosimendan did not significantly 
affect diaphragm NME (P = 0.407) (from 1.2 ± 0.2 
to 1.1 ± 0.2  cmH2O/µV) compared to placebo (from 
1.7 ± 0.5 to 2.1 ± 0.8 cmH2O/µV) assessed after 30 min of 
CPAP.
ΔPdi and ΔEAdi were higher in both the levosimendan 
and placebo groups in the CPAP trial after study medica-
tion as compared to before study medication (Fig. 1b and 
Table 2).
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Before study medication, tidal volume was equal 
between groups during the CPAP trial, but after study 
medication, there was a larger increase (P = 0.017) in 
tidal volume during CPAP in the levosimendan group 
(from 392 ± 22 to 437 ± 23  mL) compared to the pla-
cebo group (from 404 ± 32 to 418 ± 33  mL) (Fig.  1c). In 
addition, minute ventilation increased significantly more 
after levosimendan administration (P = 0.021) (Fig.  1d). 
Increased minute ventilation resulted in decreased 
 PaCO2 and increased pH in patients treated with levosi-
mendan (Table 2).
Table 2 also shows the absolute NME, ∆EAdi, P0.1, Cdyn, 
PEEPi, respiratory rate, and inspiratory time over the 
course of the study.
Effects of levosimendan on hemodynamics
Levosimendan decreased mean arterial blood pres-
sure (MAP) by 10% between the end of the CPAP trial 
before study medication (T = 0:30) and start of the CPAP 
trial after study medication (T = 5:31) (Fig. 2a, P < 0.001). 
Compared to the placebo group, MAP in the levosi-
mendan group was lower at the start of the CPAP trial 
after study medication (T = 5:31) (MAP levosimendan 
77 ± 3 and placebo 89 ± 4 mmHg; P = 0.031).
In the levosimendan group, heart rate increased 
between start of administration of study medication 
(T = 1:00) and start of the CPAP trial after study medica-
tion (T = 5:31) (Fig. 2b, P = 0.046).
Adverse events
No serious adverse events occurred between start of 
study protocol and 24 h after the end of the CPAP trial 
after study medication. Ten of 19 patients in the levosi-
mendan group (one missing value due to technical rea-
sons) developed hypotension (defined as systolic blood 
pressure < 100 mmHg or a decrease ≥ 20%) compared to 
6 patients in the placebo group (P = 0.19). Five patients 
Table 1 Patient characteristics
Data are presented as median (IQR)
BMI body mass index, MV mechanical ventilation, PS pressure support, PEEP positive end-expiratory pressure, COPD chronic obstructive pulmonary disease, RASS 
Richmond Agitation Sedation scale
Placebo (n = 19) Levosimendan (n = 20) P value
Age (yr) 63 (51–71) 67 (56–69) 0.53
BMI (kg/m2) 26.0 (23.6–28.9) 24.6 (23.3–27.3) 0.69
Gender (M/F) 13/6 10/10 0.24
Reason ICU admittance, no. (%)
 Neurological 3 (16) 0 (0) 0.11
 Pneumonia 1 (5) 4 (20) 0.34
 Sepsis non-respiratory focus 3 (16) 3 (15) > 0.99
 Post-surgery 4 (21) 6 (30) 0.52
 Exacerbation COPD 2 (11) 0 (0) 0.23
 Trauma 4 (21) 4 (20) > 0.99
 Other 2 (11) 3 (15) > 0.99
Days of MV on study day 11 (7–23) 12 (5–18) 0.61
PS level  (cmH2O) 6 (6–10) 8 (6–9.5) 0.75
PEEP level  (cmH2O) 6 (5–10) 7 (5–8) 0.55
PaO2/FiO2 ratio (mmHg) 268 (233–306) 319 (256–377) 0.08
Comorbidities, no. (%)
 COPD 8 (42) 4 (20) 0.14
 Diabetes mellitus 4 (21) 4 (20) > 0.99
 Cancer 1 (5) 2 (11) > 0.99
Relevant treatment at time of study, no. (%)
 Norepinephrine 2 (11) 6 (30) 0.24
 Steroids 6 (32) 3 (15) 0.27
 Dobutamine 0 (0) 0 (0) > 0.99
 Milrinon 0 (0) 0 (0) > 0.99
RASS CPAP trial before study medication 0 (− 1 to 0) − 1 (− 3 to 0) 0.04
RASS CPAP trial after study medication 0 (− 1 to 0) − 1 (− 3 to 0) 0.09
Delirious, no. (%) 1 (5) 5 (25) 0.18
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Fig. 1 Respiratory parameters over the course of the study day during the continuous positive airway pressure (CPAP) trial before (blue) and after 
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required volume therapy after levosimendan adminis-
tration compared to one patient in the placebo group 
(P = 0.18).
Discussion
This is the first study to investigate the effects of levo-
simendan on diaphragm function in mechanically 
ventilated ICU patients. The main findings of this physi-
ological double-blind randomized placebo-controlled 
trial can be summarized as follows: first, we found no 
effect of levosimendan on diaphragm contractile effi-
ciency. These findings are partly unexpected, given our 
previous studies that demonstrated that levosimendan 
improves in vitro contractile efficiency of the diaphragm 
in elective surgery patients and patients with COPD [17], 
and also in  vivo function of the diaphragm in healthy 
subjects [18]. Second, administration of levosimendan 
increased tidal volume, increased minute ventilation, and 
decreased  PaCO2. Third, no severe adverse events were 
reported after the administration of levosimendan.
Effects of levosimendan on diaphragm function
Critical-illness-associated respiratory muscle weakness 
may result from loss of contractile proteins (atrophy) or 
contractile protein dysfunction [5]. Indeed, only a few 
hours of controlled mechanical ventilation are associ-
ated with diaphragm atrophy in brain-dead patients 
[9, 13] and in patients after elective surgery [9]. More 
recently, we reported the development of atrophy in dia-
phragm muscle fibers of critically ill ventilated patients 
[12]. Using ultrasound, Goligher et al. [8] demonstrated 
progressive loss of diaphragm muscle thickness in ven-
tilated ICU patients with high inspiratory ventilator 
assist. Besides atrophy, diaphragm weakness in critically 
ill patients results from dysfunction of the remaining 
contractile proteins, especially reduced calcium sensi-
tivity of force generation [12, 14]. Reduced calcium sen-
sitivity implies that more calcium and thus neural input 
is required to generate force, which increases energy 
expenditure of muscle contraction.
Levosimendan is known as a cardiac inotrope, 
with vasodilating properties. On one hand, it acts by 
increasing the sensitivity of troponin C to calcium in 
myocardial fibers, hence leading to inotropy. In addi-
tion, levosimendan increases open probability of the 
mitochondrial adenosine triphosphate (ATP)-sensitive 
potassium channels in smooth muscle cells, thus result-
ing in vasodilation (for review, see [25]). Levosimendan 
is currently approved as an inotrope for acutely decom-
pensated heart failure [15, 16, 25]. In recent years, we 
have provided convincing evidence that levosimendan 
improves contractility of the diaphragm [17, 18, 26]. 
For instance, in human diaphragm muscle fibers, 
levosimendan increases calcium sensitivity of contrac-
tion by 20–30% [17], which is expected to improve con-
tractile efficiency. We have also demonstrated that the 
effects of levosimendan are more pronounced in slow-
type fibers compared to fast-type fibers [17]. It should 
be noted that levosimendan does not increase maxi-
mum force-generating capacity of the muscle fibers, as 
maximum force is independent from calcium sensitiv-
ity at saturating calcium concentration. In  vivo, levo-
simendan improved neuromechanical efficiency of the 
diaphragm by ~ 21% during both unloaded and loaded 
breathing [18]. Moreover, levosimendan reversed the 
development of diaphragm fatigue after strenuous 
loaded breathing. Based on these encouraging results 
in  vitro (increased calcium sensitivity of contraction) 
and in  vivo (improved neuromechanical efficiency of 
the diaphragm), we designed the current study. In the 
current study, measurements were performed during a 
CPAP trial, because at the time the study was designed, 
a CPAP trial was a common type of weaning trial. We 
found that levosimendan did not improve contractile 
efficiency of the diaphragm in ventilated critically ill 
patients compared to placebo. However, we did observe 
a significant increase in tidal volume and minute venti-
lation in the levosimendan group compared to placebo, 
resulting in a decrease in  PaCO2. Despite not being the 
primary endpoint, this outcome is clinically relevant as 
minute ventilation is the final common pathway of the 
respiratory system and sufficient minute ventilation is 
the key to successful weaning. The physiological mech-
anism for the increased minute ventilation remains 
speculative. First, these findings may be explained by 
an increase in central respiratory drive. As respiratory 
drive of the diaphragm (assessed by  EAdi) was not dif-
ferent after levosimendan, it can only be explained by 
altered drive to other muscles of the respiratory muscle 
pump, such as accessory inspiratory muscles or expira-
tory muscles [27]. Second, improved cardiac function 
may decrease pulmonary congestion and thus improve 
respiratory mechanics. However, dynamic lung com-
pliance was not affected by levosimendan, making this 
explanation less likely.
Interestingly, both in placebo and levosimendan 
groups, the  EAdi and Pdi increased in the second CPAP 
trial. Most likely, this reflects “normal” changes in res-
piratory drive during the day in ICU patients. As the first 
CPAP trial was performed early in the morning and the 
second in the afternoon, patients may have had some 
residual effects of sleep medication during the initial trial.
It should be noted that we expected that respiratory 
muscle function would improve in response to levosi-
mendan regardless whether low levels of pressure sup-
port, CPAP or T piece with oxygen supply were used, 
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because in healthy subjects, we found improved respira-
tory muscle function in response to levosimendan during 
both unloaded and loaded breathing [18].
Explanations for unexpected findings
There are a number of possible explanations why levosi-
mendan did not improve efficiency of the diaphragm in 
the current study. First, a too low dose of the study drug. 
In contrast to our previous study [18], we did not admin-
ister a loading dose before continuous infusion of levosi-
mendan. This was chosen to decrease the risk of severe 
hypotension, especially because weaning patients are 
often treated with diuretics. Nevertheless, the total dose 
administered before measurements was higher in the 
current study compared to our study in healthy subjects 
[18] (3.8  mg compared to 3.0  mg, respectively). Indeed, 
levosimendan resulted in a decrease in blood pressure 
(Fig. 2a), consistent with its vasodilatory effects [15, 25]. 
In addition, the administered continuous dose was also 
based on previous sepsis trials in which equal dosages 
were administered [28]. Whether higher doses of levo-
simendan are effective to improve diaphragm function 
in ventilated ICU patients remains to be investigated. In 
the current study, half of the patients treated with levo-
simendan developed hypotension, half of them received 
fluid therapy. It is, therefore, expected, using higher doses 
of levosimendan, this will result in more pronounced 
hypotension in more patients.
Second, neuromechanical efficiency the diaphragm 
(NME; ∆Pdi/∆EAdi) was chosen as the primary endpoint 
to evaluate diaphragm function. NME reflects the pres-
sure the respiratory muscles can generate for each micro-
volt of electrical activity. Previously, we demonstrated in 
healthy subjects that levosimendan improves NME of the 
diaphragm [18]. The validity of NME as outcome param-
eter depends on the quality of the Pdi and  EAdi signals. In 
the current study, mean NME values appear to be higher 
in the placebo group, this is, however, due to low  EAdi in 
one patient, resulting in a high NME. A log transforma-
tion was applied prior to the two-way repeated meas-
ures ANOVA to obtain a normal distribution of the data. 
Recently, we reported that the  EAdi processing algorithm 
of the ventilator software may limit the clinical applica-
bility of NME [29, 30]. ‘Non-physiological’  EAdi curves 
may occur as a result of flaws in the processing algorithm 
(e.g., removal of ECG) (Fig. E1 in Online Supplement), 
which affect the NME as well. In contrast to the cur-
rent study, we used raw diaphragm EMG in our in vivo 
study in healthy subjects [18]. Another notable difference 
between the current study and our study in healthy sub-
jects is that the healthy subjects had to perform inspira-
tory maneuvers of 10  s against a closed valve, resulting 
in a stable diaphragm EMG signal and, therefore, less 
vulnerable to artifacts as compared to the  EAdi signal 
obtained during a single inspiration in the current study. 
Besides technical issues regarding the primary endpoint, 
levosimendan has effects beyond calcium sensitization, 
including modulation of mitochondrial function and 
vasodilation [25]. This could have affected respiratory 
muscle function, independent from effects on NME. In a 
recent randomized controlled trial in patients with sep-
sis [31], levosimendan did not affect organ dysfunction 
(SOFA score) or mortality, but increased time to suc-
cessful weaning. It should be noted that levosimendan in 
that study was administered very early after ICU admis-
sion and not in the weaning phase. Therefore, that study 
does not preclude a beneficial effect of levosimendan on 
patients weaning from mechanical ventilation.
Third, future studies should also consider the use of 
other calcium sensitizers, despite our earlier encourag-
ing findings with levosimendan [17, 18, 26]. Alternatively, 
fast skeletal troponin activation might improve res-
piratory muscle function. Tirasemtiv amplifies the force 
response of the sarcomeres to calcium by slowing its dis-
sociation rate from the troponin complex in fast-twitch 
muscle fibers [32]. Hooijman et  al. [14] demonstrated 
that CK-2066260, an analog of tirasemtiv, increases the 
calcium sensitivity and restored contractile force of fast 
diaphragmatic muscle fibers of critically ill patients. The 
effects of CK-2066260 on diaphragm contractility in vivo 
have not been evaluated. Recently, however, tirasemtiv 
failed in a Phase 3 clinical trial in patients with amyo-
trophic lateral sclerosis due to its crossing the blood–
brain barrier [33].
Strengths and limitations
Previous studies demonstrating that levosimendan 
improves the calcium sensitivity of human diaphragm 
fibers in  vitro [17, 26] and the contractile efficiency of 
the diaphragm in healthy subjects in  vivo [18] provided 
a strong physiological rationale to perform the current 
study. In depth, physiological analysis of the diaphragm 
function was performed before and after study medica-
tion under controlled conditions (CPAP).
This study has some limitations. First, the endpoint, 
NME, has limited clinical relevance and the final effects 
of levosimendan on weaning success remain to be 
investigated. As the study protocol did not specifically 
describe criteria for extubation, reintubation, manage-
ment for extubation failure, and so on, we did not report 
data on clinical outcome after the second CPAP trial. 
Second, we did not assess the effects of levosimendan on 
cardiac function, for instance, using cardiac ultrasound. 
We specifically excluded patients with past medical his-
tory of heart failure or current use of inotropes. There-
fore, it was reasoned that changes in hemodynamic 
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condition due to levosimendan were unlikely to affect the 
primary endpoint. Third, we did not measure Pdi-twitch, 
which is the gold standard to evaluate respiratory muscle 
function and can be measured upon magnetic or electri-
cal stimulation of the phrenic nerves. We did not use this 
technique in the current study, because it can be techni-
cally challenging to perform, has limitations in tolerance, 
and cannot be applied in every patient [34]. Fourth, the 
calculated sample size was 38 patients. After finishing the 
study, it appeared that for only 37 patients the primary 
endpoint could be evaluated (one patient in each group 
was excluded). However, it seems unlikely that this would 
affect the primary outcome of the study.
In conclusion, this double-blind randomized placebo-
controlled trial demonstrates that in patients weaning 
from mechanical ventilation, levosimendan failed to 
demonstrate a direct effect on diaphragm function, but 
does increase minute ventilation. The effects of levosi-
mendan on weaning outcome remain to be studied.
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